切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2019, Vol. 07 ›› Issue (02) : 130 -134. doi: 10.3877/cma.j.issn.2095-5782.2019.02.009

所属专题: 文献

专题研究·肿瘤介入

TACE联合中药治疗不可切除肝细胞癌的研究进展
姚远1, 陈建建1, 周学良1, 焦德超1, 韩新巍1,()   
  1. 1. 450052 郑州大学第一附属医院介入放射科
  • 收稿日期:2019-03-02 出版日期:2019-05-01
  • 通信作者: 韩新巍

Research progress of TACE combined with traditional Chinese medicine in the treatment of unresectable hepatocellular carcinoma

Yuan Yao1, Jianjian Chen1, Xueliang Zhou1, Dechao Jiao1, Xinwei Han1,()   

  1. 1. Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  • Received:2019-03-02 Published:2019-05-01
  • Corresponding author: Xinwei Han
  • About author:
    Corresponding author: Han Xinwei, Email:
引用本文:

姚远, 陈建建, 周学良, 焦德超, 韩新巍. TACE联合中药治疗不可切除肝细胞癌的研究进展[J]. 中华介入放射学电子杂志, 2019, 07(02): 130-134.

Yuan Yao, Jianjian Chen, Xueliang Zhou, Dechao Jiao, Xinwei Han. Research progress of TACE combined with traditional Chinese medicine in the treatment of unresectable hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(02): 130-134.

肝细胞癌(HCC)是我国常见的恶性肿瘤之一,而对于中晚期的肝癌患者,大多数已丧失外科手术切除的机会,此时经皮肝动脉化疗栓塞术(TACE)是目前为止的首选治疗方案。虽然它有着较好的临床疗效,但其不良反应也是临床医生所必须面对的问题。传统中药由于药性温和,不良反应较少,可以减少化疗药物的用量,提高机体的免疫力,故采用TACE联合中药治疗原发性肝癌也逐渐被临床医生所推广。文章旨在综述康莱特、榄香烯、槐耳颗粒及肝复乐等中药与TACE联合治疗HCC的应用情况和优势。

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, and most patients with advanced HCC have lost the opportunity of surgical resection. At this time, TACE is by far the preferred treatment. It has better clinical efficacy, but its adverse reactions are also the problem that clinicians must face. Traditional Chinese medicine (TCM) is mild in nature and has few toxic and side effect, and it can reduce the dosage of chemotherapy drugs and improve the immunity of the body. Therefore, TACE combined with TCM for the treatment of HCC has been gradually promoted by clinicians. The purpose of this paper is to review the application and advantages of TACE combined with TCM such as Kanglaite, Elemene, Huaier and Ganfule.

[1]
Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy[J]. Pharmacol Ther,2017,173:106-117.
[2]
Singh S, Singh PP, Roberts LR,et al. Chemopreventive strategies in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol,2014,11(1):45-54.
[3]
Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. Korean J Radiol,2009,10(5):425-434.
[4]
邱力戈,梁若斯,李勇,等.HepaSphere载药微球与碘油化疗栓塞大肝癌的不良反应比较[J].中华介入放射学电子杂志,2018,6(2):99-103.
[5]
苏莹莹,刘莹钰,张扬雨,等. 9种中药注射剂联合肝动脉插管化疗栓塞术治疗原发性肝癌的网状Meta分析[J].吉林大学学报(医学版),2016,42(6):1126-1131.
[6]
李戈,赵晨,思金华,等. 19种中药注射剂联合TACE治疗中晚期肝细胞癌的网状Meta分析[J].兰州大学学报(医学版),2016,42(3):57-63,72.
[7]
石芳毓,娄丽丽,谢吻,等.中药注射剂联合肝动脉插管栓塞化疗术治疗肝癌的网状Meta分析[J].中国实验方剂学杂志,2016,22(10):180-187.
[8]
Long ZX, Wang B, Tao D,et al. Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma[J]. Oncol Lett,2015,10(1):523-527.
[9]
Cai B, Ma LM, Nong SJ,et al. Β-elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation[J]. Oncol Lett,2018,16(5):6019-6025.
[10]
Hu TL, Gao Y. Β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway[J]. Biomed Pharmacother,2018,106:1557-1562.
[11]
Wu BQ, Jiang Y, Zhu F,et al. Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703[J]. Oncol Lett,2016,11(4):2545-2551.
[12]
Fu F, Wan YD, Wu T,et al. Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: A meta-analysis[J]. J Cancer Res Ther,2014,10(Suppl 1):38-41.
[13]
Huang XL, Qin JJ, Lu S. Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantation-induced tumor growth[J]. Mol Med Rep,2014,10(4):2153-2159.
[14]
吴进录.康莱特注射液联合介入化疗治疗中晚期肝癌的临床观察[J].中国民间疗法,2015,23(12):60-61.
[15]
谢和平,李跃,王凤林,等.康莱特注射液联合肝动脉化疗栓塞术治疗原发性肝癌临床疗效[J].中成药,2018,40(12):2821-2823.
[16]
汪有锦.康莱特在肝癌介入治疗中的作用.中国中西医结合学会医学影像专业委员会第十五次全国学术大会[C].中国上海,2017.
[17]
张宜江,曹继华,徐兴东,等.康莱特联合介入化疗治疗原发性肝癌的临床研究[J].肿瘤药学,2017,7(1):104-108.
[18]
路大鹏,王玉强,赵卫林,等.康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J].世界临床医学,2017,11(5):70,72.
[19]
袁琴,王虚实,王君钰,等.榄香烯乳注射液对原发性肝癌患者免疫功能的影响[J].癌症进展,2016,14(7):664-666,670.
[20]
Wang QT, Zhang ZL, Xiong H,et al. Evaluation of the efficacy and safety of elemene in treating malignant pleural effusion caused by tumors: A PRISMA guided meta-analysis[J]. Medicine (Baltimore),2018,97(44):e12542.
[21]
Wu ZB, Wang T, Zhang YM,et al. Anticancer effects of β-elemene with hyperthermia in lung cancer cells[J]. Exp Ther Med,2017,13(6):3153-3157.
[22]
Mao YQ, Zhang JL, Hou L,et al. The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma HepG2 cells[J]. Chin J Cancer Res,2013,25(6):770-776.
[23]
杨宇辉,吴清艺,黄印强,等.榄香烯联合肝动脉化疗栓塞治疗中晚期肝癌[J].中国卫生标准管理,2017,8(18):102-103.
[24]
王小璞,赵昌林,郑丹如.榄香烯注射液联合TACE治疗晚期原发性肝癌疗效观察[J].新中医,2017,49(5):87-90.
[25]
陈德连,江会红.榄香烯联合介入治疗中晚期肝癌患者的近期疗效[J].广州中医药大学学报,2016,33(1):27-30.
[26]
Zhao GS, Liu Y, Zhang Q,et al. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy[J]. Medicine(Baltimore),2017,96(29):e7589.
[27]
Zhang CS, Zhang JL, Li X,et al. Huaier aqueous extract induces hepatocellular carcinoma cells arrest in S phase via JNK signaling pathway[J]. Evid Based Complement Alternat Med,2015,2015:171356.
[28]
Bao HD, Liu P, Jiang K,et al. Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK[J]. Oncol Lett,2016,12(2):1058-1066.
[29]
Zheng JS, Li C, Wu X,et al. Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway[J]. Int J Biol Macromol,2014,64:106-110.
[30]
Zheng JS, Li C, Wu X,et al. Astrocyte elevated gene-1(AEG-1)shRNA sensitizes Huaier polysaccharide(HP)-induced anti-metastatic potency via inactivating downstream P13K/Akt pathway as well as augmenting cell-mediated immune response[J]. Tumour Biol,2014,35(5):4219-4224.
[31]
Hu ZD, Yang AL, Su GZ,et al. Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV[J]. Sci Rep,2016,6:31298.
[32]
冯惠岗,梁奇伟,郭惠庄,等.甘草酸二铵联合槐耳颗粒治疗肝癌TACE术后栓塞综合征临床观察[J].中华介入放射学电子杂志,2016,4(4):197-201.
[33]
董德硕,刘兆玉.槐耳颗粒联合经肝动脉化疗栓塞术治疗肝细胞癌的研究进展[J].临床肝胆病杂志,2017,33(10):2021-2024.
[34]
董德硕,刘兆玉.基于真实世界肝动脉化疗栓塞术联合槐耳颗粒治疗肝细胞癌的临床研究[J].现代肿瘤医学,2018,26(5):741-746.
[35]
华向东,尚海,何忠野,等.槐耳颗粒联合经导管肝动脉化疗栓塞在原发性肝癌伴微血管侵犯根治术后的疗效分析[J].中国普外基础与临床杂志,2016,23(8):982-986.
[36]
尹剑,郭安红.肝动脉化疗栓塞联合肝复乐胶囊治疗原发性肝癌疗效及对血浆VEGF和内毒素的影响[J].现代中西医结合杂志,2018,27(24):2696-2699.
[37]
张继万,周建丽,张晓芳,等. Peg-IFN-α2a联合肝复乐胶囊对HbeAg阳性慢性乙型肝炎抗肝纤维化的疗效[J].武警医学,2017,28(3):257-260.
[38]
曹付春,韩雅莉,陈冰,等.地鳖纤溶蛋白对人脐静脉内皮细胞、肺癌、乳腺癌细胞VEGF和bFGF表达的影响[J].时珍国医国药,2011,22(8):1827-1829.
[39]
郝明志,陈武进,林海澜,等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学,2013,11(02):147-150.
[40]
周德江,何胜,翁敏.口服肝复乐联合经皮肝动脉栓塞化疗治疗中晚期原发性肝癌42例临床观察[J].医药前沿,2011,1(24):10-11.
[41]
Jiang YW, Yuan Q, Huang AB,et al. The synergistic mechanism of pemetrexed followed by kanglaite was due to KLT subsequently inhibiting the pemetrexed-activated MAPK signaling pathway[J]. Clin Lab,2015,61(10):1353-1363.
[42]
Liu Y, Zhang W, Wang XJ,et al. Antitumor effect of Kanglaite? injection in human pancreatic cancer xenografts[J]. BMC Complement Altern Med,2014,14:228.
[43]
Du X, Ye H, Zhang C,et al. Effect of kanglaite on rat cytochrome P450[J]. Pharm Biol,2014,53(7):995-1001.
[1] 李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 911-915.
[2] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 930-938.
[3] 董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[4] 黄威, 刘启, 陈流华, 滕茶香, 区喆建, 刘韩笑, 陈健聪, 张昆松. 新定义的可预测肝癌预后的焦亡相关lncRNA模型[J]. 中华普通外科学文献(电子版), 2023, 17(05): 357-365.
[5] 王荣昌, 欧奇峰, 黄晋杰, 王彩琴, 汪谦, 黄晓卉. miR-145-5p在肝细胞癌中的表达及其临床意义[J]. 中华普通外科学文献(电子版), 2023, 17(03): 197-202.
[6] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[7] 马铭秀, 徐锋, 谢铠岭, 郭亚明, 卢潼辉, 戴朝六. 术前碱性磷酸酶-前白蛋白比值对肝细胞癌切除术预后的评估价值[J]. 中华普通外科学文献(电子版), 2023, 17(02): 99-103.
[8] 尹宏祥, 段家康, 江博文, 谈燚. 全身免疫炎症指数联合预后营养指数对接受根治性切除术的肝细胞癌的预后价值研究[J]. 中华普通外科学文献(电子版), 2023, 17(02): 93-98.
[9] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[10] 曹亚娟, 黎兵华, 余德才. 转化治疗联合Laennec入路机器人右半肝切除治疗进展期肝癌[J]. 中华腔镜外科杂志(电子版), 2023, 16(02): 116-119.
[11] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[12] 吴凤芸, 滕鑫, 刘连娟. 高帧频超声造影与增强磁共振对不同直径原发性高分化肝细胞癌的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 404-408.
[13] 刘中百, 任勇军. 肝细胞癌的介入治疗现状及进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 111-115.
[14] 吴雅琴, 莫伟, 向华, 李琴, 李玉莲, 周碧芳. 肝癌患者介入术后股动脉穿刺处出血的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 352-356.
[15] 梁伟, 王晓彬, 洪笑阳, 蔡明岳, 梁礼聪, 陈烨, 黄培凯, 刘铭宇, 林立腾, 朱康顺. 原位肝癌小鼠微波消融术后复发模型的构建[J]. 中华介入放射学电子杂志, 2023, 11(02): 133-139.
阅读次数
全文


摘要